MediGene AG expects to report earnings before interest, taxes, depreciation and amortisation of €10 to €16 million in 2011, helped by milestone payments from Astellas Pharma Europe Ltd for the hormone therapy Eligard. ---Subscribe to MedNous to access this article--- Company News
